The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.
T. Tada, H. Zhou, B. M. Dcosta…·N. R. Landau
This study evaluates the neutralization resistance of SARS-CoV-2 B.1.617 and B.1.618 spike proteins to vaccine-elicited and therapeutic antibodies, finding partial resistance due to specific mutations.